Analyst Ratings for Pacific Biosciences of California (pacb)

pacb Rating Summary

pacb Price Target Summary

  |   Expand Research on pacb
Overall Rating: NEUTRAL   Rating Trend: Up   Avg. $ Target: $6.25 (+158.3%)
Date Firm Type Rating
(Past)
PT
(Past)
Start $ End $ % Chg. Details
7/30/2012 Morgan Stanley Downgrade Underweight
(Equalweight)
N/A
(N/A)
2.00 2.42 21% Details
7/27/2012 Piper Jaffray Downgrade Underweight
(Neutral)
N/A
(N/A)
1.77 2.42 36.72% Details
9/26/2011 Credit Agricole Downgrade Underperform
(N/A)
4.50
(N/A)
4.04 2.42 -40.1% Details
9/21/2011 JPMorgan Downgrade Underweight
(N/A)
8.00
(N/A)
5.56 2.42 -56.47% Details
6/21/2011 Maxim Group New Coverage Hold
(N/A)
N/A
(N/A)
11.57 2.42 -79.08% Details
4/19/2011 William Blair New Coverage Market Perform
(N/A)
N/A
(N/A)
12.95 2.42 -81.31% Details
3/17/2011 Oppenheimer New Coverage Perform
(N/A)
N/A
(N/A)
13.48 2.42 -82.05% Details
1/24/2011 Gleacher & Co. New Coverage Neutral
(N/A)
N/A
(N/A)
14.34 2.42 -83.12% Details
12/6/2010 Deutsche Bank New Coverage Buy
(N/A)
N/A
(N/A)
12.97 2.42 -81.34% Details
Like pacb Ratings? Also take a look at ROSG, GENE, GNOM

pacb Ratings News